Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

John M. Strother, Tomasz (Tom) Beer, Robert Dreicer

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested with the goal of improving on the successes of 2004. Lessons learned from other tumour types will need to be applied to prostate cancer in order to harness the bounty of available ideas. Target amplification or activating mutations and not merely the presence of a target are likely to be important to the success of targeted agents. Thus, the promise of the current crop of targeted agents is most likely to be realised when pursued in the context of well-credentialed targets and tested in highly translational clinical trials that are capable not only of assessing tumour response, but also of evaluating the status of the targeted pathway. The most promising agents in clinical development are reviewed.

    Original languageEnglish (US)
    Pages (from-to)954-964
    Number of pages11
    JournalEuropean Journal of Cancer
    Volume41
    Issue number6
    DOIs
    StatePublished - Apr 2005

    Fingerprint

    Cytotoxins
    Biological Factors
    docetaxel
    Prostatic Neoplasms
    Androgens
    Neoplasms
    Clinical Trials
    Drug Therapy
    Mutation
    Therapeutics

    Keywords

    • Chemotherapy
    • Novel agents
    • Prostate cancer
    • Targeted therapy

    ASJC Scopus subject areas

    • Cancer Research
    • Hematology
    • Oncology

    Cite this

    Novel cytotoxic and biological agents for prostate cancer : Where will the money be in 2005? / Strother, John M.; Beer, Tomasz (Tom); Dreicer, Robert.

    In: European Journal of Cancer, Vol. 41, No. 6, 04.2005, p. 954-964.

    Research output: Contribution to journalArticle

    @article{2fed8f9fd12a453fa851be38deddbc08,
    title = "Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?",
    abstract = "In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested with the goal of improving on the successes of 2004. Lessons learned from other tumour types will need to be applied to prostate cancer in order to harness the bounty of available ideas. Target amplification or activating mutations and not merely the presence of a target are likely to be important to the success of targeted agents. Thus, the promise of the current crop of targeted agents is most likely to be realised when pursued in the context of well-credentialed targets and tested in highly translational clinical trials that are capable not only of assessing tumour response, but also of evaluating the status of the targeted pathway. The most promising agents in clinical development are reviewed.",
    keywords = "Chemotherapy, Novel agents, Prostate cancer, Targeted therapy",
    author = "Strother, {John M.} and Beer, {Tomasz (Tom)} and Robert Dreicer",
    year = "2005",
    month = "4",
    doi = "10.1016/j.ejca.2005.02.002",
    language = "English (US)",
    volume = "41",
    pages = "954--964",
    journal = "European Journal of Cancer",
    issn = "0959-8049",
    publisher = "Elsevier Limited",
    number = "6",

    }

    TY - JOUR

    T1 - Novel cytotoxic and biological agents for prostate cancer

    T2 - Where will the money be in 2005?

    AU - Strother, John M.

    AU - Beer, Tomasz (Tom)

    AU - Dreicer, Robert

    PY - 2005/4

    Y1 - 2005/4

    N2 - In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested with the goal of improving on the successes of 2004. Lessons learned from other tumour types will need to be applied to prostate cancer in order to harness the bounty of available ideas. Target amplification or activating mutations and not merely the presence of a target are likely to be important to the success of targeted agents. Thus, the promise of the current crop of targeted agents is most likely to be realised when pursued in the context of well-credentialed targets and tested in highly translational clinical trials that are capable not only of assessing tumour response, but also of evaluating the status of the targeted pathway. The most promising agents in clinical development are reviewed.

    AB - In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested with the goal of improving on the successes of 2004. Lessons learned from other tumour types will need to be applied to prostate cancer in order to harness the bounty of available ideas. Target amplification or activating mutations and not merely the presence of a target are likely to be important to the success of targeted agents. Thus, the promise of the current crop of targeted agents is most likely to be realised when pursued in the context of well-credentialed targets and tested in highly translational clinical trials that are capable not only of assessing tumour response, but also of evaluating the status of the targeted pathway. The most promising agents in clinical development are reviewed.

    KW - Chemotherapy

    KW - Novel agents

    KW - Prostate cancer

    KW - Targeted therapy

    UR - http://www.scopus.com/inward/record.url?scp=16344396112&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=16344396112&partnerID=8YFLogxK

    U2 - 10.1016/j.ejca.2005.02.002

    DO - 10.1016/j.ejca.2005.02.002

    M3 - Article

    C2 - 15808961

    AN - SCOPUS:16344396112

    VL - 41

    SP - 954

    EP - 964

    JO - European Journal of Cancer

    JF - European Journal of Cancer

    SN - 0959-8049

    IS - 6

    ER -